S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)

Can Centrus Energy Grow With Focus On Cleaner Nuclear Fuel?

Thursday, December 2, 2021 | Kate Stalter
Can Centrus Energy Grow With Focus On Cleaner Nuclear Fuel?

Uranium refiner Centrus Energy (NYSEAMERICAN:LEU) is finding support near its 50-day moving average after pulling back from a November 12 high of $88.88. 

It’s gotten a boost as uranium spot prices have risen in the past seven months. 

The company reported its third-quarter on November 10, earning $2.95 per share, up from a loss of $0.83 per share in the year-ago quarter. That trounced views, which called for earnings of $0.42 per share. 

Revenue came in at $91.3 million, up 172%. 

In addition to refining uranium, Centrus operates the first U.S.-licensed production facility for high-assay low-enriched uranium fuel (HALEU) at its enrichment facility in Piketon, Ohio.

According to a June news release, “The U.S. Department of Energy (DOE) is currently supporting a three-year, $170 million dollar cost-shared demonstration project with Centrus. The company has already built 16 advanced centrifuge machines for uranium enrichment and expects to begin HALEU production by early next year.”

Next-gen Nuclear Power

While it may not be immediately clear to the uninitiated, HALEU represents a next-generation form of nuclear power, something the Biden administration is eager to prioritize. It’s efficient and cleaner than previous nuclear fuels, giving the company a competitive advantage. 

Although Centrus is a small stock, with a market capitalization of just $736.8 million, it’s been publicly traded since 1998. 

The stock broke out of a second-stage base in early September, clearing a buy point above $31 in more than double normal turnover.

As is often the case with small caps, Centrus is a volatile stock, with a beta of 1.52. That means investors and traders must use extra caution, have stops in place and be ready to pull the plug if necessary. 

On November 15, the day the stock skidded from its all-time high, Roth Capital analyst Joseph Reagor downgraded Centrus from buy to neutral. Shares slipped more than 12% in the session, on double average turnover. 

However, Reagor also boosted his price target for Centrus to $57. Given the current support at the 50-day line, and the stock’s inherent volatility, that price target doesn’t seem difficult to reach, particularly in a time frame going out 18 months from now.

While few analysts cover the stock, those who do expect Centrus to earn $4.25 per share this year, up 646% from 2020. However, that’s expected to decline sharply next year. 

"Looking forward, we are going to stay focused on pioneering the emerging market for HALEU, winning new sales, delivering strong margins, and strengthening our balance sheet," said Daniel B. Poneman, Centrus president and CEO in the earnings statement. "We are pleased with continued progress on the High-Assay, Low-Enriched Uranium demonstration program and positive momentum in our LEU segment."

Focus Heading Into 2022

While on some level that sounds like canned earnings report commentary, it does offer a strong clue as to the company’s focus heading into 2022, as well as indicating that Centrus may be putting resources into expanding the market for HALEU, rather than actively increasing the rate of profitability. 

In the earnings release, the company elaborated on the business segment revenue, which clearly showed the LEU segment has the upper hand. 

“Revenue from the LEU segment increased $13.3 million in the three months and $2.5 million in the nine months ended September 30, 2021, compared to the corresponding periods in 2020,” the company said. 

“Revenue from uranium sales decreased $5.7 million in the three months and $10.5 million in nine months ended September 30, 2021, compared to the corresponding periods in 2020. For the nine-month period, the volume of uranium sold declined 48% and the average price increased 6%,” it added.

This stock is not currently in a buy zone, although the moving-average support is potentially a good sign, and makes this stock worth watching. 
Can Centrus Energy Grow With Focus On Cleaner Nuclear Fuel?

Should you invest $1,000 in Centrus Energy right now?

Before you consider Centrus Energy, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centrus Energy wasn't on the list.

While Centrus Energy currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Centrus Energy (LEU)1.6$40.12-6.3%N/A39.33Buy$27.00
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.